C1QTNF8

Summary

C1QTNF8 (C1q and TNF related 8, HGNC:31374) is a protein-coding gene on chromosome 16p13.3, encoding Complement C1q tumor necrosis factor-related protein 8 (P60827). May play a role as ligand of RXFP1.

Involved in positive regulation of cell motility. Predicted to be located in extracellular region. Predicted to be part of collagen trimer. Predicted to be active in extracellular space.

Source: NCBI Gene 390664 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 77 total
• MANE Select transcript: NM_207419

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:31374
Approved symbol	C1QTNF8
Name	C1q and TNF related 8
Location	16p13.3
Locus type	gene with protein product
Status	Approved
Aliases	UNQ5829, CTRP8
Ensembl gene	ENSG00000184471
Ensembl biotype	protein_coding
OMIM	614147
Entrez	390664

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 2 protein_coding, 1 retained_intron

ENST00000328449, ENST00000711611, ENST00000885540

RefSeq mRNA: 1 — MANE Select: NM_207419 NM_207419

CCDS: CCDS32358

Canonical transcript exons

ENST00000328449 — 5 exons

Exon	Start	End
ENSE00001292112	1093497	1094051
ENSE00001387554	1094715	1094933
ENSE00001529165	1095615	1095788
ENSE00001529166	1096156	1096244
ENSE00002309663	1088226	1090594

Expression profiles

Bgee: expression breadth broad, 51 present calls, max score 71.75.

Top tissues by expression

116 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right uterine tube	UBERON:0001302	71.75	gold quality
ascending aorta	UBERON:0001496	68.78	gold quality
thoracic aorta	UBERON:0001515	68.60	gold quality
descending thoracic aorta	UBERON:0002345	67.59	gold quality
pituitary gland	UBERON:0000007	63.77	gold quality
adenohypophysis	UBERON:0002196	59.94	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	59.88	gold quality
left uterine tube	UBERON:0001303	53.80	gold quality
hypothalamus	UBERON:0001898	53.43	gold quality
fallopian tube	UBERON:0003889	53.30	gold quality
left coronary artery	UBERON:0001626	52.81	gold quality
right coronary artery	UBERON:0001625	52.29	gold quality
popliteal artery	UBERON:0002250	52.21	gold quality
tibial artery	UBERON:0007610	52.20	gold quality
caudate nucleus	UBERON:0001873	50.76	gold quality
substantia nigra	UBERON:0002038	49.11	gold quality
left adrenal gland cortex	UBERON:0035825	47.37	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	47.32	gold quality
right adrenal gland cortex	UBERON:0035827	46.35	gold quality
temporal lobe	UBERON:0001871	46.30	gold quality
amygdala	UBERON:0001876	46.24	gold quality
right adrenal gland	UBERON:0001233	45.81	gold quality
left adrenal gland	UBERON:0001234	45.76	gold quality
Ammon’s horn	UBERON:0001954	44.86	gold quality
adrenal gland	UBERON:0002369	43.44	gold quality
putamen	UBERON:0001874	43.12	gold quality
brain	UBERON:0000955	42.54	gold quality
hindlimb stylopod muscle	UBERON:0004252	42.30	gold quality
nucleus accumbens	UBERON:0001882	42.04	gold quality
colonic epithelium	UBERON:0000397	41.46	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.69

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

57 targeting C1QTNF8, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-433-3P	99.98	69.37	1203
HSA-MIR-3151-5P	99.86	63.83	1069
HSA-MIR-4447	99.85	67.81	2900
HSA-MIR-6842-5P	99.80	67.54	1587
HSA-MIR-7110-5P	99.80	67.84	1712
HSA-MIR-6764-5P	99.75	67.89	2304
HSA-MIR-6752-5P	99.59	67.32	1243
HSA-MIR-1915-3P	99.58	66.79	1988
HSA-MIR-4649-3P	99.56	66.90	1783
HSA-MIR-6751-5P	99.56	64.99	1145
HSA-MIR-12122	99.56	69.33	1672
HSA-MIR-671-5P	99.52	67.11	1277
HSA-MIR-6128	99.33	67.83	1581
HSA-MIR-3614-5P	99.30	65.25	837
HSA-MIR-6837-5P	99.25	65.47	1632
HSA-MIR-4685-5P	99.25	65.99	1563
HSA-MIR-6803-5P	99.19	63.90	1026
HSA-MIR-6852-5P	99.17	66.69	2073
HSA-MIR-4292	99.16	65.57	1767
HSA-MIR-6791-5P	99.16	65.92	1844
HSA-MIR-4651	99.06	67.57	2002
HSA-MIR-608	98.93	67.83	2013
HSA-MIR-2355-5P	98.83	65.51	1589
HSA-MIR-760	98.81	66.65	1392
HSA-MIR-7113-3P	98.75	65.71	1120
HSA-MIR-6840-3P	98.68	65.95	1923
HSA-MIR-6852-3P	98.54	67.60	1468
HSA-MIR-7156-3P	98.25	67.66	859

Literature-anchored findings (GeneRIF, showing 4)

• two novel human C1q/TNF family members, designated as CTRP8 and CTRP9B were described. (PMID:19666007)
• direct interaction of human CTRP8 with RXFP1 (PMID:24014093)
• This study demonstrates a novel role for CTRP8 in protecting human glioblastoma cells against the DNA alkylating damage of temozolomide, the standard chemotherapy drug used to treat glioblastoma. This DNA protective role of CTRP8 required a functional RXFP1-STAT3 signaling cascade in glioblastoma cells. CTRP8-RXFP1-STAT3 axis is an emerging new drug target for improved treatment of human glioblastoma. (PMID:29949238)
• Human C1q Tumor Necrosis Factor 8 (CTRP8) defines a novel tryptase+ mast cell subpopulation in the prostate cancer microenvironment. (PMID:36921737)

Cross-species orthologs

0 orthologs

Paralogs (23): C1QTNF3 (ENSG00000082196), COL19A1 (ENSG00000082293), PDCD7 (ENSG00000090470), COL10A1 (ENSG00000123500), C1QL1 (ENSG00000131094), C1QTNF6 (ENSG00000133466), C1QL2 (ENSG00000144119), COL8A1 (ENSG00000144810), C1QTNF2 (ENSG00000145861), C1QC (ENSG00000159189), C1QTNF7 (ENSG00000163145), C1QL3 (ENSG00000165985), COL8A2 (ENSG00000171812), C1QTNF4 (ENSG00000172247), C1QB (ENSG00000173369), C1QA (ENSG00000173372), C1QTNF1 (ENSG00000173918), ADIPOQ (ENSG00000181092), OTOL1 (ENSG00000182447), C1QL4 (ENSG00000186897), C1QTNF9B (ENSG00000205863), C1QTNF5 (ENSG00000223953), C1QTNF9 (ENSG00000240654)

Protein

Protein identifiers

Complement C1q tumor necrosis factor-related protein 8 — P60827 (reviewed: P60827)

Alternative names: C1q/TNF-related protein 8

All UniProt accessions (2): P60827, A0A3B0IWW5

UniProt curated annotations — full annotation on UniProt →

Function. May play a role as ligand of RXFP1.

Subunit / interactions. Homotrimer. Forms heteromeric complexes with C1QL1. Interacts with RXFP1.

Subcellular location. Secreted.

Tissue specificity. Expressed predominantly in lung and testis. Expressed in astrocytes.

Post-translational modifications. Not N-glycosylated.

RefSeq proteins (1): NP_997302* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001073	C1q_dom	Domain
IPR008160	Collagen	Repeat
IPR008983	Tumour_necrosis_fac-like_dom	Homologous_superfamily
IPR050822	Cerebellin_Synaptic_Org	Family

Pfam: PF00386, PF01391

UniProt features (5 total): domain 2, signal peptide 1, chain 1, region of interest 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P60827-F1	78.89	0.55

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 27 (showing top): GOCC_COLLAGEN_TRIMER, TGANTCA_AP1_C, NFE2_01, AP1FJ_Q2, NIKOLSKY_BREAST_CANCER_16P13_AMPLICON, AP1_Q6_01, MARTENS_TRETINOIN_RESPONSE_UP, ZWANG_TRANSIENTLY_UP_BY_2ND_EGF_PULSE_ONLY, ZNF436_TARGET_GENES, ZNF92_TARGET_GENES, MIR4264, DESCARTES_MAIN_FETAL_CILIATED_EPITHELIAL_CELLS, DESCARTES_FETAL_LUNG_CILIATED_EPITHELIAL_CELLS, GOBP_LOCOMOTION, GOBP_POSITIVE_REGULATION_OF_LOCOMOTION

GO Biological Process (1): positive regulation of cell motility (GO:2000147)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (3): collagen trimer (GO:0005581), obsolete extracellular space (GO:0005615), extracellular region (GO:0005576)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
positive regulation of locomotion	1
positive regulation of cellular process	1
cell motility	1
regulation of cell motility	1
binding	1
protein-containing complex	1
cellular anatomical structure	1

Protein interactions and networks

STRING

244 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
C1QTNF8	RXFP1	Q9HBX9	855
C1QTNF8	RLN2	P04090	544
C1QTNF8	OR4E2	Q8NGC2	507
C1QTNF8	OR10Z1	Q8NGY1	506
C1QTNF8	C1QL1	O75973	492
C1QTNF8	C1QL2	Q7Z5L3	491
C1QTNF8	C1QL4	Q86Z23	478
C1QTNF8	C1QL3	Q5VWW1	465
C1QTNF8	DUSP28	Q4G0W2	451
C1QTNF8	KRTAP12-3	P60328	447
C1QTNF8	OR5C1	Q8NGR4	447
C1QTNF8	OR6K6	Q8NGW6	447
C1QTNF8	OR51I2	Q9H344	447
C1QTNF8	MYCBPAP	Q8TBZ2	445
C1QTNF8	OR1I1	O60431	437
C1QTNF8	OR51I1	Q9H343	437

IntAct

4 interactions, top by confidence:

A	B	Type	Score
C1QL1	C1QTNF8	psi-mi:“MI:0915”(physical association)	0.400
C1QTNF8	VWA8	psi-mi:“MI:0914”(association)	0.350

BioGRID (17): C1QTNF8 (Affinity Capture-Western), C1QTNF8 (Affinity Capture-RNA), PLOD3 (Affinity Capture-MS), COLGALT2 (Affinity Capture-MS), SIRT3 (Affinity Capture-MS), VWA8 (Affinity Capture-MS), SATB2 (Affinity Capture-MS), C10orf2 (Affinity Capture-MS), OTUD4 (Affinity Capture-MS), LEPREL2 (Affinity Capture-MS), IMPDH1 (Affinity Capture-MS), AGGF1 (Affinity Capture-MS), FUT11 (Affinity Capture-MS), APOD (Affinity Capture-MS), MANBA (Affinity Capture-MS)

ESM2 similar proteins: A2A9Q0, A5A8Y8, A5PKD8, F1SAM7, O00468, O60500, O75325, P0C7J6, P12843, P13384, P18065, P24853, P49705, P50895, P60827, P60882, Q16270, Q24JP5, Q29400, Q2WF71, Q50LG9, Q5W7P8, Q61581, Q641Q3, Q6IQX7, Q6UKI2, Q6UWL6, Q75ZP3, Q7TSU7, Q7Z7M0, Q80W15, Q8BHA1, Q8BJ66, Q8IZ52, Q8N2S1, Q8NDA2, Q8WX77, Q91ZV8, Q96I82, Q96MS0

Diamond homologs: A1L251, F4JZC2, P0C7A1, P60827, Q3T1I2, Q5XIG2, Q6IR41, Q8BX80, Q8NFI3, Q9BXI9, Q9BXJ1, Q9QXP7, Q9SRL4, P98087, Q03692, Q05306, Q8BGU2, Q8IUK8, Q8R066, Q9BXJ0, Q9BXJ3, O75973, O88992, P23435, P63182, P86437, Q05A80, Q0II24, Q17QF9, Q4ZJM9, Q4ZJN1, Q5RJ80, Q5VWW1, Q6IMN6, Q6UW01, Q7Z5L3, Q86Z23, Q8BME9, Q8BVD7, Q8CFR0

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

77 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	74
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

595 predictions. Top by Δscore:

Variant	Effect	Δscore
16:1094929:CAGGG:C	acceptor_gain	1.0000
16:1094930:AGGG:A	acceptor_gain	1.0000
16:1094931:GGG:G	acceptor_gain	1.0000
16:1094932:GG:G	acceptor_gain	1.0000
16:1094933:GCTG:G	acceptor_loss	1.0000
16:1094934:C:CC	acceptor_gain	1.0000
16:1094934:C:T	acceptor_loss	1.0000
16:1096126:T:TA	donor_gain	1.0000
16:1093521:TG:T	donor_gain	0.9900
16:1094049:CAC:C	acceptor_gain	0.9900
16:1094053:T:A	acceptor_loss	0.9900
16:1094798:AC:A	donor_gain	0.9900
16:1094799:CC:C	donor_gain	0.9900
16:1096134:CCGT:C	donor_gain	0.9900
16:1096150:C:CA	donor_gain	0.9900
16:1094047:CTCAC:C	acceptor_gain	0.9800
16:1094052:C:CC	acceptor_gain	0.9800
16:1094791:GTCAC:G	donor_loss	0.9800
16:1094792:TCACT:T	donor_loss	0.9800
16:1094793:CACT:C	donor_loss	0.9800
16:1094794:ACTCA:A	donor_loss	0.9800
16:1094795:CTCAC:C	donor_loss	0.9800
16:1094796:T:TC	donor_loss	0.9800
16:1094797:C:CC	donor_loss	0.9800
16:1094798:A:AC	donor_gain	0.9800
16:1094798:A:AT	donor_loss	0.9800
16:1094799:C:CC	donor_gain	0.9800
16:1095622:C:A	donor_gain	0.9800
16:1096154:G:A	donor_gain	0.9800
16:1094048:TCAC:T	acceptor_gain	0.9700

AlphaMissense

1606 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
16:1093903:G:C	F119L	0.991
16:1093903:G:T	F119L	0.991
16:1093905:A:G	F119L	0.991
16:1093846:G:C	F138L	0.989
16:1093846:G:T	F138L	0.989
16:1093848:A:G	F138L	0.989
16:1093538:A:G	F241S	0.981
16:1093793:A:G	F156S	0.980
16:1093904:A:G	F119S	0.980
16:1093770:A:C	Y164D	0.979
16:1093904:A:C	F119C	0.979
16:1093847:A:C	F138C	0.977
16:1093532:C:T	G243D	0.975
16:1093523:A:T	V246D	0.972
16:1093642:G:C	S206R	0.972
16:1093642:G:T	S206R	0.972
16:1093644:T:G	S206R	0.972
16:1093813:G:C	F149L	0.972
16:1093813:G:T	F149L	0.972
16:1093815:A:G	F149L	0.972
16:1093792:G:C	F156L	0.968
16:1093792:G:T	F156L	0.968
16:1093794:A:G	F156L	0.968
16:1093534:G:C	S242R	0.967
16:1093534:G:T	S242R	0.967
16:1093536:T:G	S242R	0.967
16:1093793:A:C	F156C	0.962
16:1093660:G:C	S200R	0.961
16:1093660:G:T	S200R	0.961
16:1093662:T:G	S200R	0.961

dbSNP variants (sampled 300 via entrez): RS1000179039 (16:1097241 C>A,T), RS1000276425 (16:1092373 G>A,C), RS1000303863 (16:1088941 T>A,C), RS1000610770 (16:1091571 G>A), RS1000643131 (16:1096272 A>G), RS1000714104 (16:1096793 T>G), RS1001387325 (16:1089619 G>C), RS1001421058 (16:1090061 G>A), RS1001577332 (16:1094205 G>A), RS1001873682 (16:1089917 G>A), RS1002193823 (16:1089830 G>T), RS1002529487 (16:1095381 G>A), RS1002583410 (16:1095231 T>G), RS1002731798 (16:1098163 G>A), RS1002756011 (16:1097938 G>C,T)

Disease associations

OMIM: gene MIM:614147 | disease phenotypes: MIM:600669, MIM:617027

GenCC curated gene-disease

Mondo (3): epilepsy (MONDO:0005027), idiopathic generalized epilepsy (MONDO:0005579), hyperaldosteronism, familial, type IV (MONDO:0014875)

Orphanet (1): Familial hyperaldosteronism type IV (Orphanet:642671)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST007005_8	Logical memory (immediate recall) in normal cognition	3.000000e-07

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004874	memory performance

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D004827	Epilepsy	C10.228.140.490
C562694	Epilepsy, Idiopathic Generalized (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

8 total (human), top 8 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Acetaminophen	increases expression	1
Arsenic	decreases expression	1
Benzo(a)pyrene	affects methylation	1
Plant Extracts	affects cotreatment, decreases expression	1
Tobacco Smoke Pollution	decreases expression	1
Valproic Acid	increases methylation	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00004637	PHASE4	COMPLETED	Double-Blind, Placebo-Controlled Trial of Vitamin E as Add-on Therapy for Children With Epilepsy
NCT00043914	PHASE4	COMPLETED	Measurement Of Serum Levels Of Two Antiepileptic Drugs During Conversion In Patients With Epilepsy
NCT00132223	PHASE4	UNKNOWN	Effects on the Diagnostic Accuracy of Magnetic Imaging Angiographies of the Supra-Aortic Vessels by Three Different Magnetic Resonance Contrast Agents in Patients
NCT00133081	PHASE4	UNKNOWN	Study to Improve the Treatment of Epilepsy (SITE)
NCT00137709	PHASE4	UNKNOWN	Hormone Profiles in Adults With Newly Diagnosed Epilepsy
NCT00154076	PHASE4	COMPLETED	A Multicenter Comparative Trial of Zonisamide and Topiramate as Initial Monotherapy in Untreated Epilepsies
NCT00165828	PHASE4	TERMINATED	Efficacy and Safety of an add-on Treatment With Zonisamide in Adults With Focal Epileptic Seizures With or Without Secondary Generalization
NCT00181116	PHASE4	COMPLETED	Levetiracetam for Benign Rolandic Epilepsy
NCT00207935	PHASE4	COMPLETED	Use of Sustained Release Antiepileptic Medication (Depakote® ER) for Pediatric Epilepsy in a Mental Retardation/Developmental Disorder Population
NCT00215592	PHASE4	COMPLETED	Open Label, Zonegran (Zonisamide) In Partial Onset Seizures
NCT00266604	PHASE4	COMPLETED	A Study to Evaluate the Dosing, Effectiveness and Safety of Topiramate for the Treatment of Epilepsy
NCT00288639	PHASE4	COMPLETED	Lyrica (Pregabalin) Administered as an Add-on Therapy for Partial Seizures (LEADER).
NCT00312676	PHASE4	UNKNOWN	Compare Tolerability of an Overnight Switch to Gradual Switch Between Two Different Forms of Depakote
NCT00323947	PHASE4	COMPLETED	Methylphenidate for Treating Attention Deficit Hyperactivity Disorder in Children With Both ADHD and Epilepsy
NCT00385411	PHASE4	COMPLETED	Study of Valproate in Young Patients Suffering From Epilepsy
NCT00522418	PHASE4	TERMINATED	Study Comparing Best Medical Practice With or Without VNS Therapy in Pharmacoresistant Partial Epilepsy Patients
NCT00537940	PHASE4	COMPLETED	Comparative Study Of Pregabalin And Gabapentin As Adjunctive Therapy In Subjects With Partial Seizures
NCT00552526	PHASE4	UNKNOWN	Ketogenic Diet vs.Antiepileptic Drug Treatment in Drug Resistant Epilepsy
NCT00564915	PHASE4	COMPLETED	RCT of the Efficacy of the Ketogenic Diet in the Treatment of Epilepsy
NCT00571155	PHASE4	COMPLETED	Trial of Levetiracetam in Patients With Primary Brain Tumors and Symptomatic Seizures Who Undergo Surgery
NCT00572195	PHASE4	COMPLETED	RNS® System LTT Study
NCT00610532	PHASE4	TERMINATED	Evaluating the Transporter Protein Inhibitor Probenecid In Patients With Epilepsy
NCT00630357	PHASE4	COMPLETED	Trial to Evaluate the Safety and Efficacy of Keppra After Conversion to Mono-therapy in Subjects With Partial Epilepsy
NCT00630630	PHASE4	COMPLETED	Study on Safety and Efficacy of Levetiracetam in the Adjunctive Treatment of Female Subjects With C1 Catamenial Epilepsy
NCT00630968	PHASE4	COMPLETED	S.K.A.T.E.: Safety of Keppra as Adjunctive Therapy in Epilepsy
NCT00631150	PHASE4	COMPLETED	A Phase IV-Pharmacovigilance Study of Keppra Greece - S.K.A.T.E.: Safety of Keppra as Adjunctive Therapy in Epilepsy
NCT00659958	PHASE4	COMPLETED	ZAGAL Study: Evaluating Effectiveness and Tolerability of Zonisamide as Adjunctive Therapy in Patients With Partial Onset Seizures Treated With Two Antiepileptic Drugs
NCT00713622	PHASE4	COMPLETED	Comparing The Effect On Cognition Of Adjunctive Therapy With Zonisamide Versus Sodium Valproate
NCT00807989	PHASE4	COMPLETED	The Efficacy and Safety of Low Dose Combination of LTG and VPA Compared to CBZ Monotherapy
NCT00832884	PHASE4	COMPLETED	The Safety of Intravenous Lacosamide
NCT00869622	PHASE4	COMPLETED	Antiepileptic Drugs and Osteoporotic Prevention Trial
NCT00896987	PHASE4	COMPLETED	Lamotrigine Cognitive Function Study in Adult Untreated Epilepsies
NCT00952081	PHASE4	COMPLETED	A Pilot Study to Evaluate Efficacy and Safety of Clevidipine in Neurosurgical Patients
NCT01118455	PHASE4	TERMINATED	Trial to Assess Vagus Nerve Stimulation Therapy vs. Anti-Epileptic Drug (AED) Treatment in Children With Refractory Seizures
NCT01127165	PHASE4	COMPLETED	Low and High Dose Zonisamide in Children as Monotherapy
NCT01127256	PHASE4	COMPLETED	Comparative Study of Zonisamide and Carbamazepine as an Initial Monotherapy: Efficacy and Safety Evaluation
NCT01140867	PHASE4	COMPLETED	Open-label, Multi-center Trial of Zonisamide as Adjunctive Therapy in Patients With Uncontrolled Partial Epilepsy
NCT01175954	PHASE4	COMPLETED	Cognitive and Behavioral Effects of Lacosamide
NCT01229735	PHASE4	COMPLETED	Levetiracetam Versus Topiramate as Adjunctive Therapy to Evaluate Efficacy and Safety in Subjects With Refractory Partial Onset Seizures
NCT01244724	PHASE4	TERMINATED	Lexapro for Major Depression in Patients With Epilepsy